These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25426663)

  • 21. Clarifying the role of rasburicase in tumor lysis syndrome.
    Sood AR; Burry LD; Cheng DK
    Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical versus laboratory tumor lysis syndrome in children with acute leukemia.
    Kedar A; Grow W; Neiberger RE
    Pediatr Hematol Oncol; 1995; 12(2):129-34. PubMed ID: 7626380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of rasburicase utilization for tumor lysis syndrome management in pediatric and adult patients in the inpatient and outpatient settings.
    Abousaud MI; Rush MC; Rockey M
    J Oncol Pharm Pract; 2021 Jul; 27(5):1165-1171. PubMed ID: 32727320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome.
    Boutin A; Blackman A; O'Sullivan DM; Forcello N
    J Oncol Pharm Pract; 2019 Apr; 25(3):577-583. PubMed ID: 29320954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. More to rasburicase than uric Acid.
    Patel S; Le AN
    Pharmacotherapy; 2013 Sep; 33(9):e177. PubMed ID: 23744455
    [No Abstract]   [Full Text] [Related]  

  • 26. Metastatic gestational trophoblastic neoplasia complicated by tumor lysis syndrome, heart failure, and thyrotoxicosis: a case report.
    Schuman S; Pearson JM; Lucci JA; Twiggs LB
    J Reprod Med; 2010; 55(9-10):441-4. PubMed ID: 21043373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Recommendations of the French Society for the Control of Cancers and Leukemias in Children for the treatment of tumor lysis syndrome: results of a pediatric survey].
    Bertrand Y
    Arch Pediatr; 2005 Oct; 12 Spec No 1():13-5. PubMed ID: 17076005
    [No Abstract]   [Full Text] [Related]  

  • 28. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
    McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
    Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Rasburicase therapy may cause hydrogen peroxide shock].
    Góth L
    Orv Hetil; 2008 Aug; 149(34):1587-90. PubMed ID: 18708312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute nonlymphocytic leukemia with basophilic differentiation and t(9,11)(p22,q23) in a child.
    Kubota M; Akiyama Y; Tabata Y; Yoshigi M; Mikawa H
    Am J Hematol; 1989 Jun; 31(2):133-5. PubMed ID: 2735319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
    Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Single-dose rasburicase as treatment for tumor lysis syndrome in two patients].
    Ferrandis Rodríguez P; Llinares Tello F; Burgos San José A; Moscardó Guilleme C
    An Pediatr (Barc); 2006 Jun; 64(6):603-4. PubMed ID: 16792976
    [No Abstract]   [Full Text] [Related]  

  • 33. Risk-based management strategy and outcomes of tumor lysis syndrome in children with leukemia/lymphoma: Analysis from a resource-limited setting.
    Gopakumar KG; Seetharam S; Km JK; Nair M; Rajeswari B; Cs G; Vr P; Thankamony P
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27401. PubMed ID: 30101454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rasburicase for the treatment of tumor lysis in hematological malignancies.
    Malaguarnera G; Giordano M; Malaguarnera M
    Expert Rev Hematol; 2012 Feb; 5(1):27-38. PubMed ID: 22272702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal tubular damage in rasburicase: risks of alkalinisation.
    van den Berg H; Reintsema AM
    Ann Oncol; 2004 Jan; 15(1):175-6. PubMed ID: 14679140
    [No Abstract]   [Full Text] [Related]  

  • 36. Testing for Glucose-6-Phosphate Dehydrogenase Deficiency Before Rasburicase Use for Tumor Lysis Syndrome.
    Lakra R; Grewal US; Ramadas P
    Am J Ther; 2023 Sep-Oct 01; 30(5):e465-e467. PubMed ID: 37713696
    [No Abstract]   [Full Text] [Related]  

  • 37. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
    Vines AN; Shanholtz CB; Thompson JL
    Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumour lysis syndrome in children: experience of last decade.
    Ahn YH; Kang HJ; Shin HY; Ahn HS; Choi Y; Kang HG
    Hematol Oncol; 2011 Dec; 29(4):196-201. PubMed ID: 21710502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular findings in childhood leukemia in Brazil: high frequency of MLL-ENL Fusion/t(11;19) in infant leukemia.
    Marques EA; Neves L; Fonseca TC; Lins MM; Pedrosa F; Lucena-Silva N
    J Pediatr Hematol Oncol; 2011 Aug; 33(6):470-4. PubMed ID: 21436736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
    Cheng FM; Tien JZ; Chen TT; Yeh SP; Lin CC
    Ann Hematol; 2020 Sep; 99(9):2193-2195. PubMed ID: 32621180
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.